CTRI/2019/01/016855已完成4 期
Evaluation of efficacy and safety of various doses of oral cholecalciferol required to achieve optimal serum level of 25(OH)D among adults.
Intramural Research grant0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All the subjects of 18- 60 years of age who will be willing to give written consent for their participation in the study
排除标准
- •1.Accident or surgery in last 6 weeks.
- •2.Known TB, sarcoidosis or another granulomatous disease.
- •3.Known chronic sickness- kidney/liver/lung/bone/muscle/ heart disease/ malabsorption/ stroke.
- •4.Diabetes mellitus/ Thyroid/ parathyroid/adrenal/pituitary disease.
- •5.Cancers on treatment or treated within last 1 year.
- •6. Known autoimmune disorders or rheumatologic illnesses.
- •7. Pregnancy and lactation in last 6 months
- •8. History of any hereditary or aquired disorder related to calcium metabolism.
- •9.History of any drug intake that affects calcium or vitamin D metabolism (Steroids, Lithium, Rifampicin, Isoniazid, Ketoconazole, Statins, Aluminium hydroxide, Barbiturates, Phenytoin, Valproate, Cholestyramine, Cholestipol, Thiazide etc.)
- •10.History of intake of calcium or vitamin D supplements in last 3 months before enrolment.
- •11.History of parenteral vitamin D administration.
研究者
相似试验
招募中
2 期
Stem cell treatment for COVID-19COVID-19.COVID-19 diseaseU07.01IRCT20200421047150N1DEY Company90
进行中（未招募）
不适用
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular GoiterEUCTR2005-004451-35-NLGenzyme Europe BV99
进行中（未招募）
不适用
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter - NDMultinodular goiterMedDRA version: 6.1Level: PTClassification code 10018498EUCTR2005-004451-35-ITGenzyme Europe BV99
进行中（未招募）
不适用
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular GoiterEUCTR2005-004451-35-DKGenzyme Europe BV99
进行中（未招募）
1 期
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiterodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the normal thyroid tissue.MedDRA version: 9.1Level: LLTClassification code 10043808Term: ThyrotropinEUCTR2005-004451-35-FRGenzyme Europe BV99